Association of plasma cortisol and chronic lung disease in preterm infants.
BACKGROUND
It has been suggested that preterm infants may have developmental immaturity of the hypothalamic-pituitary-adrenal axis, and that decreased cortisol response to stress increases risk of chronic lung disease (CLD) secondary to inflammatory lung injury.


METHODS
To investigate the relationship between endogenous corticosteroid and CLD, we measured plasma cortisol during the first 28 days of life in a subset of neonates in the North American Thyrotropin-Releasing Hormone (TRH) Collaborative Trial. Analyses were performed on 314 infants, 24 to 32 weeks' gestation, whose mothers received 1 or 2 courses of antenatal corticosteroids plus TRH or placebo.


RESULTS
Mean cortisol was 3.1 microg/dL (range: 0.1-17.9) at birth, reached maximal levels at 24 hours (19.4 microg/dL, range: 0.8-124.6), and decreased to 5.9 microg/dL (range: 0.2-24.7) at 14 to 28 days of age; levels during the first week were not associated with gestational age. The Clinical Risk Index for Babies (CRIB), a neonatal assessment tool that is correlated with risk of mortality, was positively associated with cortisol level on days 1 and 3 through 7. TRH versus placebo treatment did not influence cortisol levels at any time point. To examine the relationship between cortisol and adverse outcome of death or CLD at 36 weeks' postmenstrual age (CLD36), logistic regression models adjusting for known contributing clinical factors (gestational age and CRIB score) were fit. There was a statistically borderline negative association between median cortisol level at 3 to 7 days and CLD36. After adjusting for gestational age and CRIB score, the predicted probability of CLD36 was only minimally influenced by the cortisol concentration.


CONCLUSIONS
In preterm infants, basal plasma cortisol concentration during the first week is a weak predictor for CLD36. Possible benefits as well as risks of supplemental, low-dose cortisol treatment of high-risk preterm infants remain to be determined.
Department of Pediatrics, University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104-4318, USA.
B A
BA
Banks
N
N
Stouffer
A
A
Cnaan
Y
Y
Ning
J D
JD
Merrill
R A
RA
Ballard
P L
PL
Ballard
D001997:Bronchopulmonary Dysplasia / Q000097:blood* / Q000517:prevention & control; D002908:Chronic Disease; D005260:Female; D005865:Gestational Age; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000097:blood* / Q000517:prevention & control; D008171:Lung Diseases / Q000097:blood* / Q000517:prevention & control; D010913:Pituitary-Adrenal System / Q000502:physiology; D011247:Pregnancy; D012044:Regression Analysis; D012306:Risk; D012720:Severity of Illness Index; D013973:Thyrotropin-Releasing Hormone / Q000627:therapeutic use
D005938:Glucocorticoids; D013973:Thyrotropin-Releasing Hormone; D006854:Hydrocortisone